| Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (NCT05172258) | National Cancer Institute (NCI) | 2022-07-26 |
| Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (NCT04862650) | Marcelo Bonomi | 2021-11-30 |
| Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC (NCT05047094) | Alpha Tau Medical LTD. | 2021-11-02 |
| Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor (NCT04831320) | Washington University School of Medicine | 2021-09-28 |
| Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma (NCT04643379) | Washington University School of Medicine | 2021-08-07 |
| Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC (NCT05156970) | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 2021-06-24 |
| NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer (NCT04862455) | M.D. Anderson Cancer Center | 2021-04-07 |
| Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition (NCT04454489) | Wake Forest University Health Sciences | 2021-02-25 |
| An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors (NCT04305795) | Rakuten Medical, Inc. | 2020-12-21 |
| Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer (NCT04375384) | Wake Forest University Health Sciences | 2020-07-01 |
| Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors (NCT04007744) | Mayo Clinic | 2020-02-13 |
| Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC (NCT03813836) | University College, London | 2019-07-05 |
| Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat (NCT03823131) | Chase Heaton, MD | 2019-05-02 |
| Fluciclovine F18 PET/CT in Identifying the Origin of Head and Neck Squamous Cell Carcinoma in Patients With Metastatic Cervical Nodal Disease (NCT03868020) | M.D. Anderson Cancer Center | 2019-04-24 |
| Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies (NCT03590054) | Rahul Aggarwal | 2018-08-20 |
| Standard and Delayed FDG PET/CT After Chemoradiation Therapy in Assessing Patients With Metastatic Head and Neck Squamous Cell Cancer (NCT03575949) | M.D. Anderson Cancer Center | 2018-06-15 |
| Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (NCT03522584) | University of Washington | 2018-05-17 |
| Study for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin (NCT02449681) | Rain Oncology Inc | 2015-08-01 |
| A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (NCT01602315) | Novartis Pharmaceuticals | 2012-11-12 |
| Circulating Tumor Cells as an Early Predictive head-and -Neck Squamous-cell Carcinoma (NCT02119559) | University Hospital, Montpellier | 2012-09-01 |
| Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery (NCT01468896) | National Cancer Institute (NCI) | 2011-10-26 |
| Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer (NCT00494182) | M.D. Anderson Cancer Center | 2007-04-25 |